Takeda's Entyvio meets primary endpoint in post-market study
Mar. 30, 2023 11:28 AM ETTakeda Pharmaceutical Company Limited (TAK)TKPHFBy: Jonathan Block, SA News Editor
JHVEPhoto
- A phase 4 study of Takeda Pharmaceutical Co.'s (NYSE:TAK) Entyvio met its primary endpoint in patients with ulcerative colitis.
- Results showed that at week 14, 31% of patients on Entyvio achieved remission from chronic or recurrent pouchitis compared to 10% on placebo.
- Data also showed that at week 14, the difference in improved clinical response was 30 percentage points compared to placebo. At week 34, the difference was 22.
- Results were published in the New England Journal of Medicine.
- Read why Seeking Alpha contributor Individual Trader rates Takeda (OTCPK:TKPHF) a hold.